Please use this identifier to cite or link to this item:
|Title:||Exacerbations of severe asthma in patients treated with mepolizumab|
Pavord, Ian D.
Heaney, Liam G.
Green, Ruth H.
Brightling, Chris E.
Wardlaw, Andrew J.
|Publisher:||European Respiratory Society|
|Citation:||European Respiratory Journal, 2018, 52: 1801127;|
|Abstract:||Mepolizumab, a humanised monoclonal antibody that neutralises interleukin-5, reduces exacerbations of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD) [1, 2]. The beneficial effect of treatment is most obvious in patients with a raised peripheral blood eosinophil count, a group who are at high risk of exacerbation off treatment [2, 3]. Even in this population, exacerbation rates whilst receiving mepolizumab are around one per patient per year. The nature of these remaining exacerbations has not been described. We carried out a post hoc comparison of exacerbations occurring during treatment with mepolizumab or placebo in a previously reported, double-blind, placebo-controlled trial of mepolizumab in severe eosinophilic asthma . We tested the hypothesis that exacerbations in each group differ with respect to change in symptom scores, forced expiratory volume in 1 s (FEV1) and inflammatory profile.|
|Embargo on file until:||13-Jun-2020|
|Rights:||Copyright © 2018, European Respiratory Society. Deposited with reference to the publisher’s open access archiving policy. (http://www.rioxx.net/licenses/all-rights-reserved)|
|Description:||The file associated with this record is under embargo until 18 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.|
|Appears in Collections:||Published Articles, Dept. of Infection, Immunity and Inflammation|
Files in This Item:
|ERJ Mepo manuscript 10.18.pdf||Post-review (final submitted author manuscript)||192.12 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.